Kaplan-Meier OS analysis for patients with newly diagnosed AML aged ≥60 years. (A-D) Survival analysis stratified by KRAS, NRAS, PTPN11, and EZH2 mutations among patients with ELN 2024 favorable- or intermediate-risk AML. (E-F) Survival analysis stratified by NPM1 and IDH mutations among patients with ELN 2024 favorable- or intermediate-risk AML with KRAS and EZH2 wild type.